SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
Programme SOM0044 for Parkinson’s Disease
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
Parkinson’s disease is a slowly progressive neurodegenerative disorder characterised by bradykinesia, rigidity, tremor at rest, shuffling gait and postural instability. The disease is caused by ageing, genetic and environmental factors. Symptoms usually appear around 60 years of age. Affects an estimated 10 million people worldwide. Available treatments are symptomatic, mainly involving dopaminergic agents for the control of motor function.
More About This Company
SOM Biotech Announces in Vitro Confirmation of Drug Candidates for Covid-19 in Collaboration with Ewha Woman’s University
SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of...
Partnership presentation
Unique advantages of SOMAI PRO include identification of new mechanisms of action of drugs (biological...
SOM Biotech: A Top Spanish Start-Up to Follow in 2020
SOM Biotech has made Sifted's list as one of the Top Spanish Start-ups to follow...